2017 Roadshow Announced
A series of half-day meetings to support clinical teams as they join the IBD Registry. The sessions provide protected time for teams to learn about the Biologics Audit and QI programme using the IBD Registry, and to develop local plans for Registry adoption. Each meeting will be tailored to local needs and aim to provide information, support and hands-on guidance. Experts from the Registry will be on hand to answer questions, and interactive workshops will provide practical support for teams to work together to develop your own plans. Free to attend due to generous industry sponsorship. Register at http://ibdrroadshow2017.eventreference.com/
- MON 15th MAY EXETER
- THURS 18th MAY CARDIFF
- FRI 19th MAY SHEFFIELD
- MON 22nd MAY WARRINGTON
- TUES 23rd MAY DARLINGTON
- FRI 2nd JUNE LONDON
- FRI 9th JUNE BIRMINGHAM
- AUTUMN 2017 GLASGOW
Participation continues to grow, with 91 sites now set up to enter data into the IBD Registry, and over 24,600 patient records submitted. If you have not yet registered to participate in the IBD Registry, would like help uploading your data, or have any other registry related queries please contact [email protected]
QUARTERLY DATA SUBMISSION
The next quarterly data submission will be at the end of March. If you need any help at all in preparing for this, please contact Data Manager Mark Allan by emailing [email protected]
TRUSTS IN ENGLAND – 40% DISCOUNT ON AUDIT SUBSCRIPTIONS BY 15TH MARCH
We’ve had an encouraging response to the request for subscriptions from Trusts in England to help the BSG maintain the Biologics Audit now that NHS England funding has been withdrawn.
At £2,500 per annum, the subscription is significantly less than the cost of one patient on biologics treatment for a year. Subscribers will receive benchmarked quarterly reports on the Biologics Audit KPIs focusing on quality improvement topics recommended in the last RCP Biologics Report. Later in the year, it is our intention to include reporting of HES data in relation to the Biologics data.
The BSG has offered to reduce the cost in the first year by 40% if a Trust provides a purchase order by 15th March 2017. We have written to the Chief Executives of all Trusts in England explaining the new arrangements for the Biologics Audit, putting the subscription cost in the context of overall expenditure on biologics for IBD, and reminding them that participation in the Audit is part of the NHS England Quality Accounts requirement.
Some teams have contacted us about submitting data to the IBD Registry if their Trust decides not to subscribe to the Audit. At present, you will still be able to submit data, but the Registry will not be able to provide the Trust with the benchmarked Biologics Audit reports. A copy of the letter to CEOs is available on request to [email protected]
DID YOU KNOW?
· Teams can participate in the IBD Registry using their own choice of data entry systems to suit local needs (including some existing local systems)
· Being part of the IBD Registry will give teams:
o Robust local data to manage their biologics patients and IBD service more effectively, efficiently and safely
o Evidence to benchmark the quality of their service as part of a national audit of the safety and appropriate use of biologics
With our thanks to you for your continued contribution to the IBD Registry,
Dr Stuart Bloom, IBD Registry Chair
Dr Fraser Cummings, IBD Registry Clinical Lead
DATES FOR YOUR DIARY:
· MON 15th MAY EXETER ROADSHOW
· THURS 18th MAY CARDIFF ROADSHOW
· FRI 19th MAY SHEFFIELD ROADSHOW
· TUES 23rd or WED 24th MAY DARLINGTON ROADSHOW
· FRI 2nd JUNE LONDON ROADSHOW
· FRI 9th JUNE BIRMINGHAM ROADSHOW
· WED 21 JUNE: IBD REGISTRY SYMPOSIUM AT BSG ANNUAL MEETING, MANCHESTER
· AUTUMN: GLASGOW ROADSHOW
· DECEMBER : Publication of the IBD Registry initial report
Find out more about…
The IBD Registry is recruiting three important posts to help its next phase of growth as one of the largest IBD registries in Europe. We are recruiting a Data Analytics Manager, a Projects and Operations Manager and a Data Analyst/ Developer. The roles will support...
The IBD Registry has published its first Annual Report on the Use of Biologics for Inflammatory Bowel Diseases for the year 2018-19. The report includes the cumulative results to January 2019 from April 2016 when the Registry assumed the role of supporting the National Audit of Biological Therapies from the Royal College of Physicians.
A £5m grant has been awarded by Health Data Research UK (HDR UK) to establish a health data research hub for inflammatory bowel disease (IBD). The IBD hub, to be known as Gut Reaction – The Health Data Research Hub for Inflammatory Bowel Disease, will bring together...
The IBD Registry is inviting UK IBD clinical centres to participate in a post-marketing safety study of patients using Zessly (infliximab), a biosimilar available for the treatment of Inflammatory Bowel Disease (IBD). This study is facilitated by the Registry on...
The IBD Registry is delighted a presentation prepared by the Registry’s Analytics Hub at the University of Liverpool featured in the British Society of Gastroenterology Annual Meeting in Glasgow. The Audit of biological therapy for IBD - Shawihdi et al Poster BSG 2019...